BAJAJ BROKING
Alembic Pharmaceuticals Ltd has received USFDA approval for Diltiazem Hydrochloride Extended-Release capsules in multiple dosages, strengthening its U.S. generics portfolio. Alembic Pharma share price saw notable intraday movement following the announcement.
Alembic Pharmaceuticals Ltd announced that it received final USFDA approval for its Diltiazem Hydrochloride Extended-Release capsules, a hypertension treatment. This approval allows Alembic to launch the generic equivalent of Cardizem CD capsules, a brand marketed by Bausch Health in the United States. Available in dosages of 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, these capsules cater to the U.S. market, where the product’s estimated market size is $105.3 million.
Also read: SIP Inflows Cross ₹25,000 Crore Mark for First Time in October
Drug Approval: Diltiazem Hydrochloride Extended-Release capsules approved by USFDA.
Dosage Range: 120 mg to 360 mg.
Market Value: $105.3 million for Diltiazem Hydrochloride Extended-Release.
Alembic Pharma Share Price: Closed at ₹1018.15, with notable intraday movements.
Diltiazem Hydrochloride Extended-Release capsules treat hypertension, either as a standalone treatment or combined with other antihypertensive drugs. They are also prescribed for chronic stable angina and angina related to coronary artery spasms. This approval contributes to Alembic’s generics portfolio in the U.S., a growing market for the company, which now holds 218 cumulative Abbreviated New Drug Application (ANDA) approvals from the USFDA, including 191 final approvals and 27 tentative approvals.
Also read: KPI Green Energy Board to Consider Second Bonus Share Issue in 2024
Alembic Pharma share price opened at ₹1039.00 on the BSE, surged by 2.4% to an intraday high of ₹1064.15, before easing back to ₹1018.15. This volatility reflects investor interest following the regulatory approval.
Also read: NMDC Announces 2:1 Bonus Share Issue Amid 18% Q2 Profit Growth
This new approval follows the recent successful inspection of Alembic’s oncology facility in Gujarat by the USFDA, underscoring Alembic’s strong compliance standards. Established in 1907, Alembic Pharma has built a reputation for advanced research and development, backed by its state-of-the-art manufacturing capabilities in multiple locations. The company leads in branded generics in India, supported by a large field force and approved facilities globally, including the United States.
Alembic Pharma’s latest USFDA approval for Diltiazem Hydrochloride Extended-Release capsules enhances its U.S. market presence. With this addition, Alembic is poised for continued growth in the generics sector, supported by its robust manufacturing and regulatory compliance. The Alembic Pharma share price may continue to attract investor interest as the company expands its portfolio.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Stress Testing: Meaning, How It Works, Types and Examples
20 Dec, 2024 | 5 Min. read
Hyundai Motor India Partners with Amara Raja for AGM Battery Technology
20 Dec, 2024 | 2 Min. read
KPI Green Energy Signs MoU with Rajasthan for Hybrid Solar-Wind Projects
20 Dec, 2024 | 2 Min. read
JK Cement Wins Bid for Mahan Coal Mine in Madhya Pradesh
20 Dec, 2024 | 2 Min. read
Share Market Today | Gift Nifty Hints At Consolidation Between 23,800-24,500
20 Dec, 2024 | 4 Min. read
SEBI Tightens SME IPO Rules with Focus on Financial Stability
20 Dec, 2024 | 2 Min. read
Bajaj Broking Research Desk’s Calendar Year 25 Strategy Report
20 Dec, 2024 | 2 Min. read
Know the Objective & Analysis of Ventive Hospitality IPO
20 Dec, 2024 | 3 Min. read
How to Apply for Ventive Hospitality IPO & Check Allotment Status?
20 Dec, 2024 | 3 Min. read
How to Apply for Carraro India IPO & Check IPO Allotment Status?
20 Dec, 2024 | 3 Min. read
Gold Price in India | Gold and Silver Prices Drop Amid Market Volatility
19 Dec, 2024 | 40 Min. read
How to Apply for Mamata Machinery IPO & Check Allotment Status?
19 Dec, 2024 | 3 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading